Hematology

Cells produced by this method were also shown to be more potent in animal models than cells made with typical processes.

As we learn more about genomics and identify more genes tied to rare disorders, the role of genetic counselors will become even more critical.

The senior vice president of Research & Early Development at Notch Therapeutics discussed the company’s approach to overcoming the drawbacks of autologous cell therapies.

The decision comes after a previous clinical hold delayed key medical milestones in the KEYNOTE-B79 trial.

The medical oncologists at Washington University School of Medicine in St. Louis discussed background to their research on associations between neurofilament light and neurotoxicity.

Review top news and interview highlights from the week ending October 21, 2022.

The first 6 patients dosed in the ANTLER trial had a 50% CR rate at 6 months.

Pam Gavin, executive vice president of NORD, discussed actions the organization is taking to further improve access to advanced care.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The executive director of Hemophilia Foundation Southern California discussed issues with minorities accessing care for rare diseases and strategies to mitigate them.

The approval was based on data from ZUMA-7, a phase 3 clinical trial.

With so many therapies on the horizon, the clinical and patient communities need to be adequately prepared to support them.

The first patient has been dosed in a phase 2 study of the allogeneic CAR T-cell therapy GC007g.

The director of translational research in myeloma at the Tisch Cancer Institute discussed positive findings, including a 30-month PFS in study participants.

Review top news and interview highlights from the week ending October 14, 2022.

The chief scientific officer of cell therapy at Poseida Therapeutics discussed the company’s CAR-T and TCR technologies.

The PDUFA target date is set for March 31, 2023.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

A retrospective study measured correlations of ICANS and NfL in patients with a history of diffuse large B-cell lymphoma.

ALLO-501A received RMAT designation from the FDA in June 2022.

Lyell will soon initiate a phase 1 trial of LYL845 with initial data expected in 2024.

Review top news and interview highlights from the week ending October 7, 2022.

The director of translational research in myeloma at the Tisch Cancer Institute discussed investigating sequential T cell redirection therapies.

Interim data from an ongoing study demonstrate continuing efficacy in B-NHL, CLL, and FL.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.